Ifeanyichukwu Ifechidere: Advancing Education, Research, and Laboratory Excellence in APS
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
“June is Antiphospholipid Syndrome (APS) Awareness Month – an opportunity to shine a light on a complex and often misunderstood autoimmune disorder that can have life-changing consequences.
As a biomedical scientist working in coagulation, I regularly see how critical accurate laboratory testing is in identifying patients at risk of APS.
What is Antiphospholipid Syndrome (APS)?
APS is an autoimmune condition in which the body’s immune system produces antibodies that mistakenly target phospholipid-binding proteins in the blood. These antibodies increase the risk of abnormal blood clot formation in both veins and arteries.
The condition is associated with three key laboratory markers:
- Lupus anticoagulant (LA)
- Anticardiolipin antibodies (aCL)
- Anti-β2 glycoprotein I antibodies (anti-β2GPI)
A diagnosis requires both clinical and laboratory criteria, highlighting the essential role of collaboration between clinicians and laboratory professionals.
How does APS affect someone’s life?
For many individuals, APS can be life-altering.
It may lead to:
- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
- Stroke or transient ischaemic attack (TIA)
- Recurrent pregnancy loss
- Pregnancy complications such as pre-eclampsia and placental insufficiency
Beyond the physical risks, APS can significantly impact mental wellbeing, family planning, employment, and quality of life. Many patients face long diagnostic journeys before receiving answers.
Why laboratory testing matters
Detecting APS requires specialised coagulation and immunology testing, often repeated after 12 weeks to confirm persistent antibody positivity. Accurate testing, interpretation, and adherence to guidelines are essential to avoid misdiagnosis and ensure appropriate patient management.
Raising awareness matters
Earlier recognition of APS can prevent serious thrombotic events and improve pregnancy outcomes. Increased awareness among healthcare professionals, patients, and the public is vital to reducing delays in diagnosis and treatment.
This APS Awareness Month, let’s recognise the patients living with this condition every day and continue advancing education, research, and laboratory excellence to support better outcomes.”
Find more posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A